Live feed
·
INSIDERFilingvia Quantisnow
Oncorus Inc. logo

Oncorus (ONCR) 10% owner Flynn sold 128,258 shares for $37.6K at an average $0.29

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

James E Flynn (10% owner at Oncorus Inc., ONCR) reported that they sold 128,258 shares for $37.6K at an average $0.29 between Dec 19, 2022 and Dec 21, 2022. After these transactions the filing shows 1,338,668 shares held indirectly (Through Deerfield Healthcare Innovations Fund, L.P.) and 1,338,669 shares held indirectly (Through Deerfield Private Design Fund III, L.P.).

Reporting person
Flynn James E
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Dec 19, 2022Open-market sale (S)Common Stock1, 4, 5-44,394$0.29$12.9K1,351,374 indirect
Dec 19, 2022Open-market sale (S)Common Stock1, 4, 5-44,394$0.29$12.9K1,351,374 indirect
Dec 19, 2022Open-market sale (S)Common Stock1, 4, 5-10,930$0.29$3,170332,725 indirect
Dec 20, 2022Open-market sale (S)Common Stock2, 4, 5-6,562$0.31$2,0341,344,812 indirect
Dec 20, 2022Open-market sale (S)Common Stock2, 4, 5-6,562$0.31$2,0341,344,812 indirect
Dec 20, 2022Open-market sale (S)Common Stock2, 4, 5-1,616$0.31$501331,109 indirect
Dec 21, 2022Open-market sale (S)Common Stock3, 4, 5-6,144$0.30$1,8431,338,668 indirect
Dec 21, 2022Open-market sale (S)Common Stock3, 4, 5-6,143$0.30$1,8431,338,669 indirect
Dec 21, 2022Open-market sale (S)Common Stock3, 4, 5-1,513$0.30$454329,596 indirect

Holdings before and after

  • Common Stock: 1,395,768 to 1,338,668 indirect, Through Deerfield Healthcare Innovations Fund, L.P.
  • Common Stock: 1,395,768 to 1,338,669 indirect, Through Deerfield Private Design Fund III, L.P.
  • Common Stock: 343,655 to 329,596 indirect, Through Deerfield Partners, L.P.

Footnotes from the filing

  1. 1. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.28 to $0.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1-3 of this Form 4.
  2. 2. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.30 to $0.32, inclusive.
  3. 4. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the Reporting Persons ). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ( Fund III ). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ( Deerfield Partners ). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the Funds ). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
  4. 5. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

FAQ

What did Flynn report in this ONCR Form 4?

James E Flynn (10% owner at Oncorus Inc., ONCR) reported that they sold 128,258 shares for $37.6K at an average $0.29 between Dec 19, 2022 and Dec 21, 2022. After these transactions the filing shows 1,338,668 shares held indirectly (Through Deerfield Healthcare Innovations Fund, L.P.) and 1,338,669 shares held indirectly (Through Deerfield Private Design Fund III, L.P.).

How many ONCR shares does Flynn hold after this filing?

The filing shows 1,338,668 shares held indirectly (Through Deerfield Healthcare Innovations Fund, L.P.), 1,338,669 shares held indirectly (Through Deerfield Private Design Fund III, L.P.), 329,596 shares held indirectly (Through Deerfield Partners, L.P.) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this ONCR insider sale made under a 10b5-1 plan?

The filing's footnotes do not mention a Rule 10b5-1 trading plan.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for ONCR

Earlier insider filings at ONCR

Quantisnow market dataNASDAQ
Oncorus Inc. logo
ONCR
Oncorus Inc.
Market cap
30-day
Sector
Health Care
Industry
Medicinal Chemicals and Botanical Products
Listed since
2020
Get push alerts for ONCR

Follow ONCR and get a push notification the moment its next story breaks.

Full ONCR profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONCR (Oncorus Inc.) and more on Quantisnow.